Combo Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer 8Response Rate with an Overall Survival of 13-14 months - 101967

Spotlight
Video

Combo Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer 8Response Rate with an Overall Survival of 13-14 months

Loading........
Description: Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY - MD Anderson discusses the combination of Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer with an 8% Response Rate with an Overall Survival of 13-14 months. Recorded at ASCO GI 2018.
Shared By : Gastrointestinal-Cancer-Meeting
Posted on : 01/25/18
Added : 10 months ago



Recommended

Nothing found.